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A B S T R A C T
We describe a patient with a disseminated coccidioidomycosis. Biomarkers in serum during itraconazole therapy
showed a rapid clearing of Coccidioides DNA as detected by PCR. Coccidioides antibody detection by lateral flow
assay became negative after one year and decreased from 1:64 to 1:8 in the complement fixation test after two
years. The (1 → 3)-ß-D-glucan levels normalised after two years without increase after cessation of antifungal
therapy. Biomarkers in serum may guide treatment decisions in disseminated coccidioidomycosis.
1. Introduction
Coccidioidomycosis is a systemic fungal disease, caused by the
thermally dimorphic fungus Coccidioides (C.). The two species, C. im-
mitis and C. posadasii are found in the semi-arid, desert regions of
America, including northern Mexico and different regions of South
America. C. immitis is found in central and southern California, but also
in Washington State [1], whereas infections by C. posadasii have been
reported in parts of Latin America [2] and the United States from
central and southern Arizona to western Texas and southern New
Mexico [3].
The disease is acquired by inhalation of aerosolized arthroconidia,
formed by the saprophytic mycelial form of the fungus. It is estimated
that only a minority of infected people become symptomatic at a point
to consult physicians. Among symptomatic patients, 90% experience a
self-limited respiratory illness with less than one percent progressing to
a disseminated disease [4]. Risk factors for dissemination include
African and Filipino ancestry and cell-mediated immunological defects
[5].
Besides central nervous system (CNS) and skin, skeleton is fre-
quently involved in disseminated disease and can essentially affect
every bone or joint. Lesions are generally chronic and progressive and
may lead to loss of function [6]. In one study conducted in an endemic
region, more than half of the patients who underwent surgical biopsy or
resection of osseous coccidioidomycosis had a previously documented
history of coccidioidomycosis, in mean 4.2 years prior to the surgery
[6]. In non-endemic regions these osteolytic lesions of coccidioidomy-
cosis are often suspected to be malignant tumours [6].
Coccidioides antibody detection is a helpful tool to establish a pre-
sumptive diagnosis, but biopsy is necessary to exclude an underlying
neoplastic disorder and to confirm the diagnosis by culturing of the
fungus or histopathologic demonstration of tissue forms [6].
Current treatment guidelines recommend the use of azole therapy,
unless the patients have extensive or limb-threatening skeletal or ver-
tebral disease causing imminent cord compromise in which case am-
photericin B is initially recommended eventually in association with
surgical intervention [4]. The optimal length of treatment remains
unknown, but most patients are treated for periods of 3 years to lifelong
[4]. Biomarkers in serum may help to rationalize treatment decisions
including treatment duration, but studies documenting different bio-
markers during antifungal therapy in serum are scarce. Therefore,
monitoring is not recommended in the current coccidioidomycosis
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guidelines, even if anti-Coccidioides antibody titres measured by com-
plement fixation (CF) are often used to evaluate treatment response
[4,7].
In this case description we report the detection of Coccidioides an-
tibodies, the (1 → 3)-ß-D-Glucan (BDG) and Coccidioides DNA by a
specific Coccidioides qPCR in sera of a patient with disseminated coc-
cidioidomycosis in order to illustrate their potential use in monitoring
of treatment response.
2. Case presentation
In December 2015, on day 0, a 74-year-old Caucasian male under-
went a surgical biopsy of an ulcerative tumour on his ankle.
Histopathology demonstrated spherules (Fig. 1) proving Coccidioides
osteomyelitis. On day 7, the culture on Sabouraud dextrose agar
showed growth of a mould at 30 °C and at 37 °C. Colonies were greyish
and developed after one week an aerial mycelium. Microscopic ex-
amination showed fine hyphae falling apart in barrel shaped ar-
throconidia and diagnosis of Coccidioides posadasii was confirmed by
sequencing of the partial ITS2 region (primers ITS4 and ITS5) [8]. Se-
quencing of partial 28S rDNA (primer 10F and 12R) [9] from the for-
malin fixed paraffin-embedded biopsy (FFPE) extracted DNA showed
also identification of Coccidioides.
The patients' medical history included chronic arterial hypertension.
Four years prior to the surgical sampling pneumonia was diagnosed
(Fig. 2) several weeks after a camping trip to Texas. Despite a workup
including bronchoalveolar lavage, no etiologic pathogen was identified.
No serologic tests for Coccidioides were requested. The patient's symp-
toms improved under symptomatic treatment.
On day 0, the physical examination and chest radiograph were
normal. Antibodies against Coccidioides were detected by a lateral flow
assay (LFA) and CF test with a titre of 1:64.
In the absence of symptoms or signs indicating CNS disease, anti-
fungal therapy was started using oral itraconazole (200 mg three times
per day for three days followed by 200 mg twice a day) on day 15 until
day 908. During this time the patient had to be treated by intravenous
analgesia for severe hip osteoarthritis, which needed a total hip pros-
thesis on day 487 and subsequently on day 630 a revision surgery.
We performed a retrospective analysis of the biopsy sample, as well
as of the sera (n = 15) sent for follow-up and stored at 20 °C.
2.1. Coccidioides qPCR
For serum DNA extraction, the Maxwell Blood 16 LEV DNA Kit
(Promega GmbH, Mannheim, Germany) was used as described by the
manufacturer. One extraction negative control, consisting of DNA free
water per three samples was processed in parallel to document the
absence of contamination during DNA extraction. For FFPE tissue DNA
extraction, the protocol as described by Rickerts et al was used [10].
Each of these DNAs was studied by three different qPCRs. To document
successful DNA extraction a qPCR detecting the human 18S rRNA gene
[11] was used. An internal amplification control DNA (IAC qPCR) was
used to identify PCR inhibition. Coccidioides DNA was amplified using
an inhouse Taqman qPCR assay. Primers and probe were modified from
a previously published report targeting the internal transcribed spacer
region two (ITS2) of the rRNA gene complex of Coccidioides [12]. The
primer sequences were Cocci ITS-2 fw 5′-ACCCTTCAAGCACGGCTT-3′
and Cocci ITS-2 rev 5′-TACACTCAGACACCAGGAACTC-3′, and the
probe was Cocci ITS-2 5′-6-FAM-AACGTCCCCGCTTGT-MGB-3′. Analy-
tical specificity of the in house assay was confirmed (100%) by testing
fungal DNAs (1000 pg/reaction) (Aspergillus fumigatus, Candida albicans,
Exophiala dermatitidis, Histoplasma capsulatum, Talaromyces marneffei,
Blastomyces dermatitidis, Uncinocarpus reesii, Paracoccidioides brasiliensis,
Emergomyces africanus, Emergomyces europaeus, Emmonsia parva and
Cryptococcus neoformans) and human DNA. Analytical sensitivity was
estimated at 0.001 pg/reaction using genomic DNA of a Coccidioides
isolate.
All qPCRs were performed on the Bio-Rad CFX Maestro cycler.
Samples were tested in single tubes in the human DNA detecting qPCR
and in the IAC qPCR for 40 cycles and in duplicates in the Coccidioides
qPCR for 45 cycles. If inhibition (ΔCq of ≥2 cycles) was detected and
fungal qPCRs remained negative, DNA extracted from serum samples
was diluted by a factor of 10.
The initial FFPE sample tested positive for Coccidioides DNA al-
though there was a detectable inhibition. The first serum showed evi-
dence of inhibition and was therefore retested by the specific
Fig. 1. Tissue biopsy of tumour showing characteristic (~20 μm) spherules consistent with coccidioidomycosis (Grocott's methenamine silver stain).
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Coccidioides qPCR at a 1:10 dilution. This diluted sample was tested
positive for Coccidioides DNA. All following serum samples, which were
taken after starting the therapy, remained negative in this specific qPCR
(Fig. 3 and supplement 1).
2.2. Antibody and antigen detection
Anti-Coccidioides IgG and IgM antibodies were detected by a CF test
(Histoplasma Yeast CF antigen, dilute, IMMY, USA) and a LFA (sōna
Coccidioides Ab LFA, IMMY, USA). Sera were tested retrospectively in a
single test run by semi-quantitative CF to study evolution during the
treatment avoiding interrun variation. LFA was done qualitatively as
described by the manufacturer and read visually by two laboratory
workers.
While the LFA became negative on sera after one year of treatment,
the CF titres decreased continuously to 1:8 after a little bit more than
two years of treatment (Fig. 3 and Appendix A).
Sera were also tested retrospectively for fungal antigens by a
quantitative BDG test (Fungitell assay, Associates of Cape, Cod, USA)
and became negative (< 80 pg/ml) after two years of treatment,
however peaking several times during this time (Fig. 3 and Appendix
A).
3. Discussion
Optimal treatment duration in patients with disseminated cocci-
dioidomycosis is unknown. Most patients with bone or joint involve-
ment are treated for three years to lifelong depending on the severity of
disease and the immunocompetence of the host [4]. Biomarkers may
offer insights into treatment response and personalize decisions on
treatment duration. Semi-quantitative CF tests are widely used to
monitor disease evolution. A recent study, including 434
Fig. 2. Posterior-anterior chest radiograph (a) and axial section of a CT scan (b) four years prior to diagnosis of disseminated coccidioidomycosis demonstrating
consolidation in the lower right lobe.
Fig. 3. Serologic markers and qPCR results on patient samples (sera: n = 15; FFPE: n = 1) before, during (day 15- day 908) and after antifungal therapy.
Complement fixation titre (CF, red line) and (1→ 3)-ß-D-Glucan assay (BDG, blue line) over time after starting therapy are displayed. Under the diagram are resumed
the results of the tests: the specific Coccidioides qPCR (qPCR), the lateral flow assay (LFA) and the BDG (negative under 80 pg/ml, blue striped area). FFPE = formalin
fixed paraffin-embedded tissue. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)
D. Wilmes, et al. Medical Mycology Case Reports 29 (2020) 25–28
27
coccidioidomycosis patients, described the titre trends under therapy
[7]. The authors set the cut-off value for complicated infections (dis-
seminated infections and CNS involvement) at ≥1:32. Titre reduction
rates for disseminated disease were ≥4 month per dilution, but about a
third of these patients were serologic nonimprovers (who failed to de-
crease of at least one dilution step a year), as our patient, without
evidence to affect clinical outcomes.
The place of antibody detection by LFA in the monitoring of dis-
seminated coccidioidomycosis has not been studied so far. In our pa-
tient the LFA remained positive during the first year, as long as CF titres
were ≥1:32.
BDG, as a component of the cell wall of many fungal pathogens is
independent of the immunological status of the patient and has sub-
sequently a potential advantage in the diagnosis in immunosuppressed
patients who may have undetectable specific antibody titres and in
patients with hyperacute coccidioidomycosis. But data concerning
sensitivity of this assay in coccidioidomycosis is limited.
One study of 12 patients showed serum BDG assay positivity (≥80
pg/ml) in> 90% of disseminated disease [13]. However, in another
study by Thompson et al., serum BDG was detectable> 31 pg/ml in
83% and elevated in only 10% of patients with disseminated and me-
ningeal cases (n = 44) [14]. The explanation of the authors was a
possible compartmentalization of BDG in the central nervous system in
CNS coccidioidomycosis [14]. So far, there is only scarce data on the
value of BDG as follow-up marker in coccidioidomycosis. Thompson
et al. found that BDG values correlated poorly with serum coccidioidal
CF antibody titres an observation that is now confirmed by us [14]. In
our patient, BDG was initially positive and decreased unsteadily below
80 pg/ml after 2 years. The decline of this measurement was marked by
several peaks which weren't accompanied by an increase of the CF ti-
tres. Two of these peaks coincided with the patient's orthopaedic
treatment by intravenous analgesia and a prosthetic hip replacement
which needed surgical revision. It is known, that the administration of
certain drugs (e.g. intravenous immunoglobulins or albumin) or sur-
gical procedures (e.g. abdominal surgery) can cause false-positive BDG
results [15]. Another reason for this could be the more or less panfungal
nature of BDG leading to elevated levels not only in coccidioidomycosis
but also in other invasive fungal diseases [15]. However, no other
fungal infection was diagnosed in our patient.
We performed additionally a specific Coccidioides qPCR on an FFPE
tissue sample from the resected tumour [12]. Even if spherules are
specific for coccidioidomycosis, they are not found in around 19% of
skeleton biopsies [6] and if they are found may be difficult to distin-
guish from rhinosporidiosis and adiasporomycosis [16,17].
The examination by Coccidioides qPCR of all sera, showed a positive
result only in the first sample. One prior publication showed that
Coccidioides DNA could be amplified through another C. immitis specific
qPCR in 6 out of 64 sera and cerebrospinal fluid (CSF) that were pro-
vided for antibody detection tests. Of these PCR positive tested sera and
CSF, four were antibody negative but developed subsequently positive
titres [18]. However PCR positivity was transient and disappeared as
antibodies appeared [18]. In our patient antibodies and Coccidioides
DNA were detectable at the same time but DNA cleared rapidly with the
start of itraconazole therapy.
In conclusion, detection of Coccidioides DNA from serum suggests
the potential of qPCR as a non-invasive diagnostic tool for the diagnosis
of disseminated infections in untreated patients. The application on
pathology blocks may improve diagnosis in the absence of character-
istic spherules. Subsequent failure to detect DNA from serum may serve
as an indicator of early treatment response, but suggests low diagnostic
yield in treated patients. The CF antibody and the BDG test significantly
decrease after 2–3 years. During that time, peaks of BDG may be ob-
served without obvious worsening of disease.
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